Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7263170 | 0.85 | TSHR (0.63) | TSHRTDP1CYP3A4ATMRECQL | |
| SCHEMBL6133318 | 0.84 | TSHR (0.71) | TSHRTDP1CYP3A4ATMRECQL | |
| SCHEMBL2462155 | 0.83 | TSHR (0.63) | TSHRTDP1CYP3A4ATMRECQL | |
| SCHEMBL516622 | 0.83 | TSHR (0.66) | TSHRTDP1CYP3A4ATMRECQL | |
| Acrylic Acid SCHEMBL516623 | 0.82 | TSHR (0.74) | TSHRTDP1CYP3A4ATMRECQL | |
| SCHEMBL560438 | 0.81 | TSHR (0.81) | TSHRTDP1CYP3A4ATMRECQL | |
| SCHEMBL6133312 | 0.80 | TSHR (0.64) | TSHRTDP1CYP3A4ATMRECQL | |
| SCHEMBL5025197 | 0.80 | TSHR (0.58) | TSHRTDP1CYP3A4ATMRECQL | |
| SCHEMBL4125846 | 0.80 | TSHR (0.58) | TSHRTDP1CYP3A4ATMRECQL | |
| Acrylic Acid SCHEMBL11282590 | 0.80 | TSHR (0.71) | TSHRTDP1CYP3A4ATMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050226919-A1 | Device for transdermal administration for the treatment of urinary tract disorders | UCB PHARMA GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1293198-B1 | Device for transdermal administration for the treatment of urinary tract disorders | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-02-09 | — | — | EP | disclosed |
| EP-1293198-A1 | Device for transdermal administration for the treatment of urinary tract disorders | SCHWARZ PHARMA AG (DE) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050226919-A1 | Device for transdermal administration for the treatment of urinary tract disorders | AR, CYP17A1, TACR1 | TSHR 465/4885TDP1 4163/4885CYP3A4 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.